Immuneering IMRX Stock
1.45 USD
{{ price }}
-0.684931%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqGM
Market Cap
52.54M USD
LOW - HIGH [24H]
1.43
-
1.49 USD
VOLUME [24H]
47.04K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-2.04 USD
Immuneering Price Chart
Immuneering IMRX Financial and Trading Overview
| Immuneering stock price | 1.45 USD |
| Previous Close | 9.32 USD |
| Open | 9.62 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 1000 |
| Day's Range | 9.32 - 10.56 USD |
| 52 Week Range | 3.7 - 16.17 USD |
| Volume | 63.95K USD |
| Avg. Volume | 75.87K USD |
| Market Cap | 288.1M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.04 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.83 USD |
IMRX Valuation Measures
| Enterprise Value | 185.81M USD |
| Trailing P/E | N/A |
| Forward P/E | -4.852217 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2162.0342 |
| Price/Book (mrq) | 2.6686535 |
| Enterprise Value/Revenue | 1394.376 |
| Enterprise Value/EBITDA | -3.493 |
Trading Information
Immuneering Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 114.13% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 16.17 USD |
| 52 Week Low | 3.7 USD |
| 50-Day Moving Average | 9.5 USD |
| 200-Day Moving Average | 8.2 USD |
IMRX Share Statistics
| Avg. Volume (3 month) | 75.87K USD |
| Avg. Daily Volume (10-Days) | 76.6K USD |
| Shares Outstanding | 29.25M |
| Float | 14.86M |
| Short Ratio | 24.14 |
| % Held by Insiders | 27.61% |
| % Held by Institutions | 47.09% |
| Shares Short | 1.82M |
| Short % of Float | 11.63% |
| Short % of Shares Outstanding | 6.21% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -40147.97% |
| Gross Margin | 49.51% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -25.70% |
| Return on Equity (ttm) | -42.35% |
Income Statement
| Revenue (ttm) | 133.25K USD |
| Revenue Per Share (ttm) | 0.005 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 158.83K USD |
| EBITDA | -53193492 USD |
| Net Income Avi to Common (ttm) | -51221364 USD |
| Diluted EPS (ttm) | -1.88 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 91.54M USD |
| Total Cash Per Share (mrq) | 3.13 USD |
| Total Debt (mrq) | 4.74M USD |
| Total Debt/Equity (mrq) | 4.85 USD |
| Current Ratio (mrq) | 17.054 |
| Book Value Per Share (mrq) | 3.691 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -46238244 USD |
| Levered Free Cash Flow (ttm) | -28011524 USD |
Profile of Immuneering
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 245 Main Street |
| ZIP | 02142 |
| Phone | 617 500 8080 |
| Website | https://immuneering.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 68 |
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Q&A For Immuneering Stock
What is a current IMRX stock price?
Immuneering IMRX stock price today per share is 1.45 USD.
How to purchase Immuneering stock?
You can buy IMRX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Immuneering?
The stock symbol or ticker of Immuneering is IMRX.
Which industry does the Immuneering company belong to?
The Immuneering industry is Biotechnology.
How many shares does Immuneering have in circulation?
The max supply of Immuneering shares is 36.23M.
What is Immuneering Price to Earnings Ratio (PE Ratio)?
Immuneering PE Ratio is now.
What was Immuneering earnings per share over the trailing 12 months (TTM)?
Immuneering EPS is -2.04 USD over the trailing 12 months.
Which sector does the Immuneering company belong to?
The Immuneering sector is Healthcare.
Immuneering IMRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Global Market Composite NQGM | 1839.71 USD — |
-3.16
|
— — | 1825.54 USD — | 1881.06 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4131.38 USD — |
-1.41
|
— — | 4109.33 USD — | 4165.2 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4148.65 USD — |
+0.54
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}